Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Adding atezolizumab to standard bevacizumab-chemotherapy extends survival in recurrent cervical cancer. Final data from the phase 3 BEATcc trial show a median overall survival of nearly 32 months vs. 22.7 months without the immunotherapy — a meaningful gain for a hard-to-treat population. Notably, the benefit held regardless of PD-L1 status, and the regimen is now a preferred first-line option in NCCN guidelines.
The phase 3 BEATcc trial has delivered its final verdict: adding atezolizumab to bevacizumab plus chemotherapy meaningfully extends survival for patients with metastatic, persistent, or recurrent cervical cancer. Presented at the ESMO Congress 2026, the long-term data confirm a durable overall survival (OS) benefit at a median follow-up of nearly five years — reinforcing the regimen's place as a frontline standard of care.
One of the standout findings is that the survival benefit was consistent regardless of PD-L1 status, suggesting that biomarker testing may not be necessary when selecting patients for this regimen — a clinically significant simplification. The regimen has already been incorporated into the latest NCCN guidelines as a preferred first-line option, irrespective of PD-L1 expression.
By the Numbers:
Why it matters: Recurrent cervical cancer carries a poor prognosis with limited treatment options. These final BEATcc results confirm that atezolizumab-based combination therapy offers a substantial and durable survival advantage — and the PD-L1-agnostic benefit could streamline treatment decisions for oncologists worldwide.
